Navigation Links
Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
Date:7/3/2008

NAPA, Calif., July 3 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced termination of the Invicorp(R) License Agreement with Ardana Bioscience Limited ("Ardana"). The Agreement was a license to manufacture, market, sell and distribute Invicorp(R) in Europe and was terminated pursuant to the Company's contractual rights, precipitated by Ardana's entry into voluntary administration on June 27, 2008.

Mr. Frank Massino, Senetek's Chairman and Chief Executive Officer stated, "We have advised Ardana of the Invicorp(R) License termination and served demand for return of all related clinical and regulatory data. We have received a number of inquiries regarding the availability of the European license and we are confident this will be a valuable and productive asset in the hands of the right partner".

Invicorp(R), is a highly safe and effective treatment for erectile dysfunction ("ED"), a condition that affects more than 100 million men worldwide. Invicorp(R) is expected to capture a significant share of the moderate-to-severe ED market and become the therapy of choice for second-line ED treatment. Invicorp(R) has received marketing authorization in Denmark as well as in England. Additionally, Invicorp(R) has been approved in New Zealand. Senetek has entered into an exclusive licensing and collaborative marketing agreement for the commercialization of Invicorp(R) with Plethora Solutions for the North American market.

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2007. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM)
2. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
3. Senetek PLC Announces Key Personnel Appointments
4. Senetek PLC Reports 2007 Financial Results
5. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
6. Senetek PLC Announces Launch of New Website
7. Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology
8. Senetek PLC Reports Third Quarter 2007 Financial Results
9. Mylan Announces Tentative FDA Approval for Generic Version of Antibiotic Zyvox(R) Tablets
10. Hooper Holmes Announces Sale of Claims Evaluation Division
11. Transition Therapeutics Announces Executive Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... through a world of exterior design possibilities. CertainTeed, North America’s leading brand of ... by expanding the product offerings showcased in the mobile version of the ColorView® ...
(Date:2/12/2016)... ... ... Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter Teen Dance. ... and without special needs to gather in a safe and supportive environment. Volunteers will be ... place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, 322 Elks ...
(Date:2/12/2016)... ... 2016 , ... Planet Future is a Final Cut Pro X ... for showcasing pictures, videos as well as text in an exciting cartoon environment. Planet ... and a beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert media ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : ... Well Managed Mind” (published by Balboa Press) teaches readers how to become their own ... profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal ...
(Date:2/11/2016)... Jersey (PRWEB) , ... February 11, 2016 , ... Registered ... a free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” on ... Community in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA Consultants, ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... IRVINE, Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: ... quarter ended December 31, 2015. The Company also filed its ... fiscal year 2016 with the Securities and Exchange Commission today. ... December 31, 2015 --> --> ... 2015 increased $2.6 million, or 95%, to $5.4 million from ...
(Date:2/11/2016)... has committed to provide drug disposal kiosks in ... as part of a program to combat drug ... organization As You Sow. Conrad MacKerron , Senior ... to unneeded drugs because they lack easily accessible collection and ... Conrad MacKerron , Senior Vice President at As You ...
(Date:2/11/2016)... -- Potrero Medical, Inc., the developer of the Accuryn™ critical ... George M. Rapier, III , MD, to its Board ... WellMed is one of the nation,s largest physician owned practice ... Texas and Florida ... internal medicine practice, he has been instrumental to the company,s ...
Breaking Medicine Technology: